StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note released on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
Shares of Galmed Pharmaceuticals stock opened at $0.39 on Wednesday. Galmed Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $7.80. The company’s 50 day moving average price is $0.36 and its two-hundred day moving average price is $0.38.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last issued its earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- Stock Splits, Do They Really Impact Investors?
- MarketBeat Week in Review – 4/22 – 4/26
- What is Put Option Volume?
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Invest in Blue Chip Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
